New British Study Names Top Prognostic Markers for Mesothelioma, According to Surviving Mesothelioma

Share Article

UK scientists say some markers are better than others for predicting mesothelioma prognosis and monitoring treatment response.

Predicting Mesothelioma Prognosis with Biomarkers

Prognostic Biomarkers for Mesothelioma

Neutrophil-lymphocyte ratio and baseline TGV predict prognosis in malignant pleural mesothelioma.

Researchers in Bristol, UK have recently identified three prognostic biomarkers that they believe will help clinicians deliver better care to people with pleural mesothelioma. Click here to read the full article, which has just been posted on the Surviving Mesothelioma website.

The South West Area Mesothelioma and Pemetrexed trial included 73 pleural mesothelioma patients recruited between 2008 and 2011. Each was measured for total glycolytic volume (TGV), mesothelin, and neutrophil-to-lymphocyte ratio.

Lead author Dr. Claire Hooper of the North Bristol Lung Centre concludes, “Neutrophil-lymphocyte ratio and baseline TGV predict prognosis in malignant pleural mesothelioma (MPM), but PET-CT is unhelpful in monitoring chemotherapy response.”

In addition, the report in the British Journal of Cancer, found that, while mesothelin levels were not valuable for predicting prognosis, they could be helpful in measuring treatment response.

“Deciding on a treatment approach and then determining whether or not it is working are two major challenges for mesothelioma patients,” says Surviving Mesothelioma’s Managing Editor, Alex Strauss. “If these findings can be validated in further studies, it could not only make that process easier but potentially improve outcomes for many people.”

For more information on each of the biomarkers studied and what they mean, see Mesothelioma Prognosis and Treatment Response: Some Markers More Useful than Others, now available on the Surviving Mesothelioma website.

Hooper, CE, “The South West Area Mesothelioma and Pemetrexed Trial: a multicenter prospective observational study evaluating novel markers of chemotherapy response and prognostication”, March 10, 2015, British Journal of Center, Epub ahead of print, http://www.nature.com/bjc/journal/vaop/ncurrent/full/bjc201562a.html

For nearly ten years, Surviving Mesothelioma has brought readers the most important and ground-breaking news on the causes, diagnosis and treatment of mesothelioma. All Surviving Mesothelioma news is gathered and reported directly from the peer-reviewed medical literature. Written for patients and their loved ones, Surviving Mesothelioma news helps families make more informed decisions.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Michael Ellis
Cancer Monthy
+1 (919) 570-8595
Email >
Follow us on
Visit website